Value Analysis - ATRS Short Then Position Long

NASDAQ:ATRS   Antares Pharma, Inc
ATRS is showing strong growth on the books with ever-increasing revenue per year, positive EPS , and ever-improving equity and asset management.

The 10 years discounted cash flows model indicates that the company's stock is currently undervalued at between $4.39 and $5.64 (26.9% - 63%)

Technical analysis indicates that bulls have oversaturated the market and we may see a retracement of 6-8% before the share price continues to climb.
Comment: I should probably stop trying to find exact movements. ATRS is up!